Daniel F. Hoth

2.4k total citations
56 papers, 1.8k citations indexed

About

Daniel F. Hoth is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Daniel F. Hoth has authored 56 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Oncology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daniel F. Hoth's work include HIV Research and Treatment (9 papers), HIV/AIDS drug development and treatment (8 papers) and Statistical Methods in Clinical Trials (6 papers). Daniel F. Hoth is often cited by papers focused on HIV Research and Treatment (9 papers), HIV/AIDS drug development and treatment (8 papers) and Statistical Methods in Clinical Trials (6 papers). Daniel F. Hoth collaborates with scholars based in United States, Malaysia and Italy. Daniel F. Hoth's co-authors include Brian Leyland‐Jones, Margaret I. Johnston, Paul V. Woolley, Philip S. Schein, Susan A. King, K Clagett-Carr, B Leyland-Jones, John S. Macdonald, R. Wittes and Silvia Marsoni and has published in prestigious journals such as Science, Journal of Clinical Oncology and Blood.

In The Last Decade

Daniel F. Hoth

55 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel F. Hoth United States	23	669	528	246	231	229	56	1.8k
Raymond W. Klecker United States	23	848 1.3×	810 1.5×	199 0.8×	489 2.1×	311 1.4×	41	2.4k
Minya Pu United States	29	674 1.0×	646 1.2×	188 0.8×	165 0.7×	161 0.7×	74	2.4k
Fang Yu United States	30	527 0.8×	1.2k 2.3×	180 0.7×	247 1.1×	244 1.1×	87	2.6k
F. M. Schabel United States	22	1.2k 1.7×	1.1k 2.0×	365 1.5×	177 0.8×	34 0.1×	59	2.9k
Xicheng Wang China	25	1.2k 1.7×	904 1.7×	528 2.1×	188 0.8×	280 1.2×	205	2.8k
Renzo Canetta United States	30	2.2k 3.2×	894 1.7×	502 2.0×	124 0.5×	82 0.4×	61	3.9k
Marcel Rozencweig Belgium	30	1.9k 2.9×	998 1.9×	695 2.8×	121 0.5×	55 0.2×	151	4.0k
Susan C. Aitken United States	20	426 0.6×	344 0.7×	66 0.3×	364 1.6×	156 0.7×	32	1.5k
Steven Lacy United States	19	419 0.6×	333 0.6×	311 1.3×	134 0.6×	72 0.3×	29	1.2k

Countries citing papers authored by Daniel F. Hoth

Since Specialization

Citations

This map shows the geographic impact of Daniel F. Hoth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel F. Hoth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel F. Hoth more than expected).

Fields of papers citing papers by Daniel F. Hoth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel F. Hoth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel F. Hoth. The network helps show where Daniel F. Hoth may publish in the future.

Co-authorship network of co-authors of Daniel F. Hoth

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel F. Hoth. A scholar is included among the top collaborators of Daniel F. Hoth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel F. Hoth. Daniel F. Hoth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ellenberg, S S, et al.. (1993). Discussion: Susan Ellenberg, M W Myers and D F Hoth, the use of external monitoring committees in trials of infectious diseases. Statistics in Medicine. 12. 1 indexed citations

Hoth, Daniel F.. (1993). Issues in the Development of a Prophylactic HIV Vaccine. Annals of the New York Academy of Sciences. 685(1). 777–783. 4 indexed citations

Ellenberg, Susan S., Maureen Myers, William C. Blackwelder, & Daniel F. Hoth. (1993). The use of external monitoring committees in clinical trials of the national institute of allergy and infectious diseases. Statistics in Medicine. 12(5-6). 461–467. 12 indexed citations

Feinberg, Judith & Daniel F. Hoth. (1992). Current Status of HIV Therapy. Hospital Practice. 27(9). 161–174. 7 indexed citations

Hoth, Daniel F., Maureen Myers, & Daniel S. Stein. (1992). Current Status of HIV Therapy. Hospital Practice. 27(9). 145–156. 2 indexed citations

Ellenberg, Susan S., Ellen Cooper, Dianne M. Finkelstein, et al.. (1992). Studying treatments for AIDS: New challenges for clinical trials—a panel discussion at the 1990 annual meeting of the society for clinical trials. Controlled Clinical Trials. 13(4). 272–292. 6 indexed citations

Feinberg, Judith & Daniel F. Hoth. (1991). Current Status of HIV Therapy: II. Opportunistic Diseases. Hospital Practice. 26(3). 105–113. 3 indexed citations

Vermund, Sten H. & Daniel F. Hoth. (1990). How can epidemiology assist in guiding interventions for the acquired immunodeficiency syndrome/human immunodeficiency virus?. Annals of Epidemiology. 1(2). 141–155. 6 indexed citations

McGowan, John J., Joseph E. Tomaszewski, James C. Cradock, et al.. (1990). Overview of the Preclinical Development of an Antiretroviral Drug, 2′,3′-Dideoxyinosine. Clinical Infectious Diseases. 12(Supplement_5). S513–S521. 40 indexed citations

10.

Hoth, Daniel F. & Maureen Myers. (1990). Current Status of HIV Therapy: I. Antiretroviral Agents. Hospital Practice. 26(1). 174–197. 3 indexed citations

11.

Hoth, Daniel F., et al.. (1988). Development and Testing of AIDS Vaccines. Science. 241(4864). 426–432. 91 indexed citations

12.

Grem, Jean L., Daniel F. Hoth, Brian Leyland‐Jones, et al.. (1988). Teniposide in the treatment of leukemia: a case study of conflicting priorities in the development of drugs for fatal diseases.. Journal of Clinical Oncology. 6(2). 351–379. 13 indexed citations

13.

O’Dwyer, Peter J., Susan A. King, Jacqueline Plowman, et al.. (1988). Pyrazole: preclinical reassessment. Investigational New Drugs. 6(4). 305–310. 10 indexed citations

14.

Clagett-Carr, K, Gisele Sarosy, Jacqueline Plowman, Daniel F. Hoth, & B Leyland-Jones. (1988). N-methylformamide: cytotoxic, radiosensitizer, or chemosensitizer.. Journal of Clinical Oncology. 6(5). 906–918. 9 indexed citations

15.

Marsoni, Silvia, Daniel F. Hoth, Richard Simon, et al.. (1987). Clinical drug development: an analysis of phase II trials, 1970-1985.. PubMed. 71(1). 71–80. 63 indexed citations

16.

Grem, Jean L., Dale Shoemaker, Daniel F. Hoth, et al.. (1987). Arabinosyl-5-azacytosine: A novel nucleoside entering clinical trials. Investigational New Drugs. 5(4). 315–328. 18 indexed citations

17.

O’Dwyer, Peter J., Susan A. King, Daniel F. Hoth, & Brian Leyland‐Jones. (1987). Role of thymidine in biochemical modulation: a review.. PubMed. 47(15). 3911–9. 66 indexed citations

18.

Schein, P S, et al.. (1980). Phase I clinical trial of spirogermanium.. PubMed. 64(10-11). 1051–6. 29 indexed citations

19.

Smith, Frederick P., Daniel F. Hoth, Bernard Levin, et al.. (1980). 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer. 46(9). 2014–2018. 93 indexed citations

20.

Schein, Philip S., et al.. (1978). Sensitivity of human and murine hematopoietic precursor cells to 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose and 1,3-bis(2-chloroethyl)-1-nitrosourea.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 38(2). 257–60. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact